Tamoxifen modulation of carboplatin cytotoxicity in a human U-138 glioma cell line

Clinical Neurology and Neurosurgery

Volumn 100, Issue 2, 1998, Pages 89-93

  Mastronardi, Luciano ^a   Farah, Jibril Osman ^a   Puzzilli, Fabrizio ^a   Ruggeri, Andrea ^a  

^a Civilian Hospital   (Italy)

Author keywords

Carboplatin; Glioma; Glioma cell line; Protein kinase C; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PROTEIN KINASE C; TAMOXIFEN; TRYPAN BLUE;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; ENZYME ACTIVITY; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN DETERMINATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRAIN NEOPLASMS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLIOMA; HUMANS; PROTEIN KINASE C; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0031825989     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-8467(98)00004-3     Document Type: Article

References (34)

1. Kornblith PL, Walker M Chemotherapy for malignant gliomas. J Neurosurg. 68:1988;1-17.
2. Mahaley MS Jr, Mettlin C, Natarajan N, Laws ER, Peace BB National survey on patterns of care for brain-tumor patients. J Neurosurg. 71:1989;826-836.
3. Müller H, Brock M, Ernst H Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas. Clin Neurol Neurosurg. 87:1985;167-171.
4. Salcman M Survival in glioblastoma: historical perspective. Neurosurgery. 7:1980;435-438.
5. Bianco AR, De Placido S, Gallo C, Pagliarulo C, Marinelli A, Petrella G, D'Istria M, Delrio G Adjuvant therapy with tamoxifen in operable breast cancer: 10 year results of the Neaples (GUN) study. Lancet. 2:1988;1095-1099.
6. Corey RW, Davis JM, Zervas NT Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Treat Rev. 65:1981;793-795.
7. Berd D, McLaughlin CJ, Hart E, Wiebe VJ, Masfrangel MJ, Bellet RE, Degregorio MW Short course high dose tamoxifen with cytotoxic chemotherapy for metastatic melanoma. Proc Am Soc Clin Oncol. 10:1991;291.
8. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res. 50:1990;7134-7138.
9. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB Inhibition of protein kinase C by tamoxifen. Cancer Res. 45:1985;2462-2465.
10. Zhang W, Yamada H, Sakai N, Niikawa S, Nozawa Y Enhancement of radiosensitivity by tamoxifen in C6 glioma cells. Neurosurgery. 31:1992;725-730.
11. Feun LG, Stewart DJ, Maor M A pilot study of cisdiammine-dichloroplatinum and radiation therapy in patients with high grade astrocytomas. J Neurooncol. 1:1983;109-113.
12. Stewart DJ, O'Bryan RM, Al-Sarraf M Phase II study of cysplatin in recurrent astrocytomas in adults: a Southwest Oncology Group study. J Neurooncol. 1:1983;145-147.
13. Walker RW, Dautis E, Shapiro WR Treatment of recurrent glioma with carboplatin (CBDCA). Proc Am Soc Clin Oncol. 6:1987;A281.
14. Doz F, Berens ME, Dougherty DV, Rosenblum ML Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposure. J Neurooncol. 11:1991;27-35.
15. Gainon P, Ettinger LJ, Baum E Carboplatin appears active in progressive childhood brain stem glioma, medulloblastoma and ependymoma. Proc Am Soc Clin Oncol. 7:1988;A312.
16. Warnick RE, Pradof MD, Mack EE A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol. 19:1994;69-74.
17. Guseo A Rapid determination of CSF lymphocyte subsets by labeled microspheres. J Neuroimmunol. 13:1986;117-122.
18. Couldwell WT, Antel JP, Apuzzo MLJ, Yong VW Inhibition of growth of established human glioma lines by modulators of the protein kinase-C system. J Neurosurg. 73:1990;594-600.
19. Couldwell WT, Antel JP, Apuzzo MLJ, Yong VW Enhanced protein kinase-C activity determines the growth rate of malignant human gliomas. J Neurosurg. 74:1991;368A.
20. Couldwell WT, Uhm J, Antel JP, Yong VW Enhanced protein kinase C activity correlates with the growth rate of malignant human gliomas. Neurosurgery. 29:1991;880-887.
21. Couldwell WT, Antel JP, Yong VW Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas: part II. Effects of glioma mitogens and modulators of PKC. Neurosurgery. 31:1992;717-724.
22. Couldwell WT, Hinton DR, He S, Chen T, Sabit I, Weiss MH, Law RE Protein Kinase C inhibitors induce apoptosis in human malignant glioma lines. FEBS Lett. 345:1994;43-46.
23. Bhat NR Role of protein kinase C in glial cell proliferation. J Neurosci Res. 22:1989;20-27.
24. Couldwell WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS, Apuzzo MJ Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery. 32:1993;485-490.
25. Greenberg DA, Carpenter CL, Messing RO Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res. 47:1987;70-74.
26. Legha SS Tamoxifen in the treatment of breast cancer. Ann Intern Med. 109:1988;219-228.
27. Baltuch G, Couldwell WT, Villemure JG, Yong VW Protein Kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery. 33:1993;495-501.
28. Gewirtz RJ, Barnett GH, Cohen BH, Lupica KM. Response to tamoxifen in patients failing conventional therapy for malignant glioma. In: Abstract Book of the 62nd Annual Meeting of AANS, San Diego, April 9-14, 1994:525.
29. Vertosick FT, Selker RG, Pollack IF, Arena V The treatment of intracranial malignant glioma using orally administered tamoxifen therapy: preliminary results in a series of 'failed' patients. Neurosurgery. 30:1992;897-903.
30. Vertosick FT, Selker RG, Arena V. A dose-escalation study of tamoxifen therapy in patients with recurrent glioblastoma multiforme. In: Abstract Book of the 62nd Annual Meeting of AANS, San Diego, April 9-14, 1994:116.
31. Endicott JA, Ling V The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 58:1989;137-174.
32. McClay EF, Albright KB, Jones JA, Eastman A, Christen RD, Howell SB Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res. 52:1992;6790-6796.
33. McClay EF, Albright KB, Jones JA, Christen RD, Howell SB Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res. 53:1993;1571-1576.
34. McClay EF, Albright KB, Jones JA, Christen RD, Howell SB Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer. 55:1993;1018-1022.